ImageneBio, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
ImageneBio, Inc. (IMA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $1.13 per share for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2025-07-24
- ImageneBio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $1.08, a 44.90% decline year-over-year.
- ImageneBio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $1.96, a 74.38% decline year-over-year.
- ImageneBio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-03-31 was $7.65, a 52.39% increase year-over-year.
- ImageneBio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2021-03-31 was $5.02.
- ImageneBio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $1.13, a 51.71% decline from fiscal 2023.
- ImageneBio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $2.34, a 57.61% decline from fiscal 2022.
- ImageneBio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $5.52, a 9.95% decline from fiscal 2021.
- ImageneBio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2021 was $6.13, a 73.65% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2024-12-31 | $1.13 10-K · filed 2025-03-06 | |||
| 2024-09-30 | $1.13 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | $1.10 10-Q · filed 2025-07-24 | |||
| 2024-03-31 | $1.08 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $2.34 10-K · filed 2025-03-06 | |||
| 2023-09-30 | $2.25 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | $2.23 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | $1.96 10-Q · filed 2024-05-13 | |||
| 2022-12-31 | $5.52 10-K · filed 2024-03-12 | |||
| 2022-09-30 | $6.04 10-Q · filed 2022-11-07 | |||
| 2022-06-30 | $6.04 10-Q · filed 2022-08-11 | |||
| 2022-03-31 | $7.65 10-Q · filed 2022-05-12 | |||
| 2021-12-31 | $6.13 10-K · filed 2023-03-14 | |||
| 2021-09-30 | $5.78 10-Q · filed 2021-11-10 | |||
| 2021-06-30 | $5.55 10-Q · filed 2021-08-12 | |||
| 2021-03-31 | $5.02 10-Q · filed 2021-05-13 | |||
| 2020-12-31 | $3.53 10-K · filed 2022-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |